vebreltinib + epidermal growth factor receptor inhibitor

**Vebreltinib + epidermal growth factor receptor inhibitor** is a combination regimen used primarily in oncology, particularly for the treatment of non-small cell lung cancer (NSCLC) that has genetic alterations driving activation of both the mesenchymal-epithelial transition (c-Met) receptor and the epidermal growth factor receptor (EGFR) pathway. Vebreltinib is a potent, selective, orally bioavailable small molecule inhibitor of c-Met (hepatocyte growth factor receptor), while "epidermal growth factor receptor inhibitor" refers to one of several tyrosine kinase inhibitors (e.g., osimertinib, gefitinib, erlotinib, dacomitinib) that specifically block EGFR signaling. Mechanistically, the combination targets both c-Met and EGFR kinases, aiming to overcome resistance to single-agent EGFR inhibition, especially in tumors where MET amplification or activation confers resistance. This dual inhibition disrupts proliferation, survival, and metastatic signaling driven by both pathways. The combination is being investigated in clinical studies, notably in NSCLC patients who have failed prior EGFR TKI therapy and have developed MET-driven resistance[1][5].

Other names

bozitinib + epidermal growth factor receptor inhibitor